Granulomatous hepatitis, a mystery solved. Read more about Granulomatous hepatitis, a mystery solved.
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Read more about Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. Read more about Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation.
Evidence and choice: The BCLC vision for tailoring clinical decision-making. Read more about Evidence and choice: The BCLC vision for tailoring clinical decision-making.
AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation. Read more about AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation. Read more about Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. Read more about Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist. Read more about HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Read more about BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Non-invasive alloimmune risk stratification of long-term liver transplant recipients. Read more about Non-invasive alloimmune risk stratification of long-term liver transplant recipients.
